Switch Therapeutics
Mike brings twenty years of corporate finance and life science expertise to Switch. Most recently, he was the Senior Vice President of Finance & Operations at Kezar Life Sciences, where he played at integral role in building the company from its inception to a multiple clinical program, development-stage company. Prior to Kezar’s launch in 2015, Mike served as the Head of R&D Finance at Onyx Pharmaceuticals, Inc. until its’ acquisition by Amgen, Inc. in 2013. Previously, he served in commercial finance at Mentor Corporation, a Johnson & Johnson subsidiary, pre-and post-acquisition. Mike’s career in the life sciences sector began at Amgen, Inc. where he held a number of positions of increasing responsibility within the finance organization. He began his finance career at 3Com Corporation, Inc., a leader in the manufacturing and sale of computer networking products, acquired by Hewlett Packard in 2010. Mike earned a Bachelor of Science, in Business Administration from California Polytechnic State University, San Luis Obispo.
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.